U.K. to require more disclosure of drug trial data

The tug of war between regulators and drug developers over clinical trial data has been escalating in the UK. Now the government will require developers to turn over data after GlaxoSmithKline was accused of dragging its feet on releasing data indicating that its antidepressant Seroxat is linked to an elevated risk of suicide among teens.

Critics have long contended that Big Pharma companies are notoriously slow about releasing data that could raise concerns about therapies. British authorities say that a tightening of the laws should make that impossible.

Glaxo, meanwhile, has vigorously denied acting improperly over the release of Seroxat data. The suicide risk was only evident after all the trial data was reviewed collectively, says Glaxo, rather than one trial at a time. And once it knew about the danger, adds Glaxo, the company alerted regulators around the world.

- read the article in the Wall Street Journal

Related Articles:
Could full data disclosure avert scandal? Report
UK patients sue for Paxil withdrawal. Report
Study highlights link between Paxil and suicide. Report
Top 10 Drug Warnings and Recalls of 2007. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.